Iron Administration Via Colonic TET Combined With WMT for ID

At least 60 subjects who meet all the inclusion criteria but do not meet any exclusion criteria will be enrolled in this study. Data of demographic characteristics, reticulocyte hemoglobin, ferritin and clinical outcomes will be collected. After treatment, they will enter the follow-up period for safety and efficacy evaluation.

Inclusion criteria

• ferritin ≤30 μg/L;
• feasible colonic TET placement (cephalic end in the ileocecal region);
• completion of 3 WMT sessions.

Exclusion criteria

• The patient has other co-morbidities that can lead to iron deficiency, such as acute gastrointestinal haemorrhage and menorrhagia.etc.
• People who are allergic to iron or taking oral medications that interfere with iron absorption.
• Patients with heart, brain, lung, liver, kidney and other serious diseases;
• Patients do not cooperate to complete the clinical trial process;